Effect of pegylation on pharmaceuticals
10.1038/nrd1033
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Drug Discovery (297)
Bibliography

Harris, J. M., & Chess, R. B. (2003). Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery, 2(3), 214–221.

Authors 2
  1. J. Milton Harris (first)
  2. Robert B. Chess (additional)
References 75 Referenced 2,952
  1. Clark, A. Formulation of proteins and peptides for inhalation. Drug Deliv. Syst. Sci. (In the press).
  2. Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459–476 (2002). An excellent review that covers the chemistry and synthesis of first- and second-generation pegylation processes. (10.1016/S0169-409X(02)00022-4) / Adv. Drug Delivery Rev. by MJ Roberts (2002)
  3. Mateo, C. et al. Removal of amphipathic epitopes from genetically-engineered antibodies: production of modified immmunoglobulins with reduced immunogenicity. Hybridoma. 19, 436–471 (2000). (10.1089/027245700750053959) / Hybridoma. by C Mateo (2000)
  4. Lyczak, J. B. & Morrison, S. L. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein. Arch. Virol. 139, 189–196 (1994). (10.1007/BF01309464) / Arch. Virol. by JB Lyczak (1994)
  5. Syed, S. et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 89, 3242–3252 (1997). (10.1182/blood.V89.9.3243) / Blood. by S Syed (1997)
  6. Allen, T. M. Liposomes: opportunities in drug development. Drugs 54 Suppl. 4, 8–14 (1997). (10.2165/00003495-199700544-00004) / Drugs by TM Allen (1997)
  7. Sebeni, J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15, 57–88 (1998). / Crit. Rev. Ther. Drug Carrier Syst. by J Sebeni (1998)
  8. Bailon, P. & Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1, 352–356 (1998). (10.1016/S1461-5347(98)00086-8) / Pharm. Sci. Technol. Today by P Bailon (1998)
  9. Zaplinsky, S. Harris, J. M. In Chemistry and Biological Applications of Polyethylene Glycol (American Chemical Society Symposium Series 680) 1–15 (San Francisco, 1997). / Chemistry and Biological Applications of Polyethylene Glycol by S Zaplinsky (1997)
  10. Gabizon, A. & Martin, F. Polyethylene glycol-coated liposomal doxorubicin. Drugs 54 Suppl. 4, 15–21 (1997). (10.2165/00003495-199700544-00005) / Drugs by A Gabizon (1997)
  11. Yamaoka, T., Tabata, Y. & Ikada, Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83, 601–606 (1994). (10.1002/jps.2600830432) / J. Pharm. Sci. by T Yamaoka (1994)
  12. Working, P. K. et al. In Chemistry and Biological Applications of Polyethylene Glycol (American Chemical Society Symposium Series 680) 45–57 (San Francisco, 1997). (10.1021/bk-1997-0680.ch004) / Chemistry and Biological Applications of Polyethylene Glycol by PK Working (1997)
  13. Richter, A. W. & Akerblom, E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethyleneglycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70, 124–131 (1983). (10.1159/000233309) / Int. Arch. Allergy Appl. Immunol. by AW Richter (1983)
  14. Cheng, T. et al. Acclerated clearance of polethylene glycol modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem. 10, 520–528 (1999). (10.1021/bc980143z) / Bioconjug. Chem. by T Cheng (1999)
  15. Davis, F. F. et al. Enzyme polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. 4, 169–173 (1978). (10.1007/978-1-4684-6985-1_35) / Enzyme Eng. by FF Davis (1978)
  16. Davis, F. F. et al. In Peptide and Protein Drug Delivery (ed Lee, V. H. L.) 226–231 (Marcel Dekker, New York, 1990). / Peptide and Protein Drug Delivery by FF Davis (1990)
  17. Nucci, M. L., Schorr, R. & Abuchowski, A. The therapeutic value of polyethylene glycol modified protein. Adv. Drug Deliv. Rev. 6, 133–151 (1991). (10.1016/0169-409X(91)90037-D) / Adv. Drug Deliv. Rev. by ML Nucci (1991)
  18. Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001). This article describes the pharmacodynamics and pharmacokinetics advantages of pegylation for clinical drugs. (10.2165/00003088-200140070-00005) / Clin. Pharmacokinet. by JM Harris (2001)
  19. Kozlowski, A. & Harris, J. M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 72, 217–224 (2001). A detailed review of the pharmaceutical uses of pegylated proteins as human therapeutics. (10.1016/S0168-3659(01)00277-2) / J. Control. Release by A Kozlowski (2001)
  20. Monfardini, C. et al. A branched monomethoxypolyethylene glycol for protein modification. Bioconjug. Chem. 6, 62–69 (1995). (10.1021/bc00031a006) / Bioconjug. Chem. by C Monfardini (1995)
  21. Koslowski, A., Charles, S. A. & Harris, J. M. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419–429 (2001). A detailed discussion of the clinical development of pegylated interferon for treating hepatitis C. (10.2165/00063030-200115070-00001) / BioDrugs by A Koslowski (2001)
  22. Katre, N. V. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv. Drug Deliv. Rev. 10, 91–114 (1993). (10.1016/0169-409X(93)90005-O) / Adv. Drug Deliv. Rev. by NV Katre (1993)
  23. Zaplinsky, S. & Lee, C. In Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications (ed Harris, J. M.) 347–370 (Plenum Press, NewYork, 1992). / Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications by S Zaplinsky (1992)
  24. Kinstler, O. B. et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13, 996–1002 (1996). (10.1023/A:1016042220817) / Pharm. Res. by OB Kinstler (1996)
  25. Zaplinsky, S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16, 157–182 (1995). (10.1016/0169-409X(95)00023-Z) / Adv. Drug Deliv. Rev. by S Zaplinsky (1995)
  26. Harris, J. M. Synthesis of polyethylene glycol derivatives. J. Macromol. Sci. Rev. C25, 325–373 (1985). (10.1080/07366578508081960) / J. Macromol. Sci. Rev. by JM Harris (1985)
  27. Dust, J. M, Fang, Z. H. & Harris, J. M. Proton NMR characteristics of polyethylene glycol and derivatives. Macromolecules 23, 3742–3746 (1990). (10.1021/ma00218a005) / Macromolecules by JM Dust (1990)
  28. Bentley, M. D. & Harris, J. M. Polyethylene glycol aldehyde hydrates and related polymers and applications in modifying. US Patent 5, 990, 237 (1999).
  29. Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343–346 (1990). / Biotechnology by RJ Goodson (1990)
  30. El Tayar, N. et al. Polyo-IFN-β conjugates. WO 99/55377 (1999).
  31. Zaplinsky, S. et al. New detachable polyethylene glycol conjugates:Cysteine-cleavable lipopolymers regenerating natural phospholipid. Bioconjug. Chem. 10, 703–710 (1999). (10.1021/bc990031n) / Bioconjug. Chem. by S Zaplinsky (1999)
  32. Yokoyama, M. et al. Synthesis of polyethylene oxide with heterobifunctional reactive groups at its terminals by an anionic inititator. Bioconjug. Chem. 3, 275–276 (1992). (10.1021/bc00016a003) / Bioconjug. Chem. by M Yokoyama (1992)
  33. Bentley, M. D., Harris, J. M. & Kozlowski, A. Heterobifunctional polyethylene glycol derivatives and methods for their preparation. WO 126692A1 (2001).
  34. Yamasaki, N., Matsuo, A. & Isobe, H. Novel polyethylene glycol derivatives for modification of proteins. Agric. Biol. Chem. 52, 2125–2127 (1988). / Agric. Biol. Chem. by N Yamasaki (1988)
  35. Veronese, F. M. & Caliceti, P. Branched and linear polyethylene glycol influence of the polymer structure on enzymological, pharmacokinetic and immunological properties of protein conjugates. J. Bioact. Compat. Polym. 12, 196–207 (1997). (10.1177/088391159701200303) / J. Bioact. Compat. Polym. by FM Veronese (1997)
  36. Hershfield, M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency. Clin. Immunol. Immunopathol. 76, S228–232 (1995) (10.1016/S0090-1229(95)90306-2) / Clin. Immunol. Immunopathol. by MS Hershfield (1995)
  37. Burnham N. L. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51, 210–218 (1994). / Am. J. Hosp. Pharm. by NL Burnham (1994)
  38. Hillman, B. C. & Sorensen, R. U. Management options: SCIDS with adenosine deaminase deficiency. Ann. Allergy 72, 395–404 (1994). / Ann. Allergy by BC Hillman (1994)
  39. Hershfield, M. S. In Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications (ed Harris, J. M.) 145–154 (Plenum Press, NewYork, 1992). / Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications by MS Hershfield (1992)
  40. Keating, M. J. et al. L-asparaginase and PEG asparaginase — past, present, and future. Leuk. Lymphoma 10, 153–157 (1993). (10.3109/10428199309149129) / Leuk. Lymphoma by MJ Keating (1993)
  41. Holle, L. M. Pegasparagase: an alternative. Ann. Pharmacother. 3, 616–624 (1997). (10.1177/106002809703100517) / Ann. Pharmacother. by LM Holle (1997)
  42. Physicians' Desk Reference, 53 edition 2600–2601 (Thomson PDR, Montvale, New Jersey, 1999).
  43. Liang, J. T. et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann. Intern. Med. 132, 296–305 (2000). (10.7326/0003-4819-132-4-200002150-00008) / Ann. Intern. Med. by JT Liang (2000)
  44. Grace, M. et al. Structural and biologic characterization of pegylated recombinant IFN-α2b. J. Interferon. Cytokine. Res. 21, 1103–1115 (2001). (10.1089/107999001317205240) / J. Interferon. Cytokine. Res. by M Grace (2001)
  45. Glue, P. et al. PEG-interferon-α2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatology 30, 189A (1999). / Hepatology by P Glue (1999)
  46. Linday, K. L. et al. A randomized double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395–403 (2001). (10.1053/jhep.2001.26371) / Hepatology by KL Linday (2001)
  47. O'Brien, C. et al. A double-blind, mult-icenter randomized, parallel dose-comparison study of six regimens of 5kD linear peginterferon α-2a compared with Roferon-A in patients with chronic hepatitis C. Antivir. Ther. 4, 15 (1999). (10.1177/135965359900400102) / Antivir. Ther. by C O'Brien (1999)
  48. Bailon, P. et al. Pharmacological properties of five polyethylene glycol conjugates of interferon α-2a. Antivir. Ther. 4, 27 (1999). / Antivir. Ther. by P Bailon (1999)
  49. Algranati, N. E., Sy, S. & Modi, M. A branched methoxy 40 kDa polyethylene glycol moiety optimizes the pharmacokinetics of PEG–IFN. Hepatology 30, 190A (1999). / Hepatology by NE Algranati (1999)
  50. Zeuzem, S. et al. Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666–1672 (2000). (10.1056/NEJM200012073432301) / N. Engl. J. Med. by S Zeuzem (2000)
  51. Heathcote, E. J. et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673–1680 (2000). (10.1056/NEJM200012073432302) / N. Engl. J. Med. by EJ Heathcote (2000)
  52. Liang, J. T. et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132, 296–305 (2000). (10.7326/0003-4819-132-4-200002150-00008) / Ann. Intern. Med. by JT Liang (2000)
  53. McHutchinson, J. G. et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339, 1485–1492 (1998). (10.1056/NEJM199811193392101) / N. Engl. J. Med. by JG McHutchinson (1998)
  54. Poynard, T. et al. Randomized trial of interferon α-2b plus ribavirin for 48 weeks versus interferon α-2b placebo for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426–1432 (1998). (10.1016/S0140-6736(98)07124-4) / Lancet by T Poynard (1998)
  55. Sulkowski, M. S. et al. Pegylated interferon α-2a and ribavirin combination therapy for chronic hepatitis C. Gastroenterology 118, 950 (2000). (10.1016/S0016-5085(00)85944-2) / Gastroenterology by MS Sulkowski (2000)
  56. Manns, M. P. et al. Peginterferon α-2b plus ribavirin compared to interferon α-2b plus ribavirin for the treatment of chronic hepatitis C. Lancet 358, 958–965 (2001). (10.1016/S0140-6736(01)06102-5) / Lancet by MP Manns (2001)
  57. Fried, M. W. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975–982 (2002). (10.1056/NEJMoa020047) / N. Engl. J. Med. by MW Fried (2002)
  58. Drake W. M. et al. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur. J. Endocrinol. 145, 451–456 (2001). (10.1530/eje.0.1450451) / Eur. J. Endocrinol. by WM Drake (2001)
  59. Van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754–1759 (2001). (10.1016/S0140-6736(01)06844-1) / Lancet by AJ Van der Lely (2001)
  60. Edwards, C. K. PEGylated recombinant human soluble tumor necrosis factor receptor type I. Ann. Rheum. Dis. 58, 173–181 (1999). (10.1136/ard.58.2008.i73) / Ann. Rheum. Dis. by CK Edwards (1999)
  61. Moreland, L. W. et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. 27, 601–609 (2000). / J. Rheumatol. by LW Moreland (2000)
  62. Choy E. H. et al. Efficacy of a novel pegylated humanized anti-tnf fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded randomized dose-escalating trial. Rheumatology 41, 1133–1137 (2002). (10.1093/rheumatology/41.10.1133) / Rheumatology by EH Choy (2002)
  63. Crawford, J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat. Rev. 28, 7–11 (2002). (10.1016/S0305-7372(02)80003-2) / Cancer Treat. Rev. by J Crawford (2002)
  64. Bence, A. K. & Adams, V. R. Pegfilgrastim: a new therapy to prevent neutropenic fever. J. Am. Pharm. Assoc. (Wash) 42, 806–808 (2002). (10.1331/108658002764653595) / J. Am. Pharm. Assoc. (Wash) by AK Bence (2002)
  65. Gordon, A. N. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312–3322 (2001). (10.1200/JCO.2001.19.14.3312) / J. Clin. Oncol. by AN Gordon (2001)
  66. Park, J. W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95–99 (2002). (10.1186/bcr432) / Breast Cancer Res. by JW Park (2002)
  67. Zhao, X. & Harris, M. J. Novel degradable polyethylene glycol hydrogels for controlled release of protein. J. Pharm. Sci. 87, 1450–1458 (1998). (10.1021/js980065o) / J. Pharm. Sci. by X Zhao (1998)
  68. Gillinov, A. M. & Lytle, B. W. A novel synthetic sealant to treat air leaks at cardiac reoperation. J. Card. Surg. 16, 255–257 (2001). An overview of the synthesis, characterization and potential uses of pegylated hydrogels (10.1111/j.1540-8191.2001.tb00517.x) / J. Card. Surg. by AM Gillinov (2001)
  69. Wain, J. C. et al. Trial of a novel synthetic sealant in preventing air leaks after lung resection. Ann. Thorac. Surg. 71, 1623–1628 (2001). (10.1016/S0003-4975(01)02537-1) / Ann. Thorac. Surg. by JC Wain (2001)
  70. Ferland, R., Mulani, D. & Campbell, P. K. Evaluation of a sprayable polyethylene gylcol adhesion barrier in a porcine efficacy model. Human Reprod. 16, 2718–2723 (2001). (10.1093/humrep/16.12.2718) / Human Reprod. by R Ferland (2001)
  71. Hinds, K. D. & Skim, S. W. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54, 505–530 (2002). (10.1016/S0169-409X(02)00025-X) / Adv. Drug Deliv. Rev. by KD Hinds (2002)
  72. Weir, A. N. et al. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30, 512–516 (2002) (10.1042/bst0300512) / Biochem. Soc. Trans. by AN Weir (2002)
  73. Rocca, M. et al. Pathophysiological and histomorphological evaluation of polyacryloylmorpholine vs polyethylene glycol modified superoxide dismutase in a rat model of ischemia/reperfusion injury. Int. J. Artif. Organs. 19, 730–734 (1996). (10.1177/039139889601901209) / Int. J. Artif. Organs. by M Rocca (1996)
  74. Calvo, P. et al. Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157–1165 (2001). (10.1023/A:1010931127745) / Pharm. Res. by P Calvo (2001)
  75. Shi, N. et al. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18, 1091–1095 (2001). (10.1023/A:1010910523202) / Pharm. Res. by N Shi (2001)
Dates
Type When
Created 22 years, 6 months ago (Feb. 28, 2003, 3:17 p.m.)
Deposited 1 year, 7 months ago (Jan. 9, 2024, 12:50 a.m.)
Indexed 2 days, 22 hours ago (Sept. 4, 2025, 9:29 a.m.)
Issued 22 years, 6 months ago (March 1, 2003)
Published 22 years, 6 months ago (March 1, 2003)
Published Print 22 years, 6 months ago (March 1, 2003)
Funders 0

None

@article{Harris_2003, title={Effect of pegylation on pharmaceuticals}, volume={2}, ISSN={1474-1784}, url={http://dx.doi.org/10.1038/nrd1033}, DOI={10.1038/nrd1033}, number={3}, journal={Nature Reviews Drug Discovery}, publisher={Springer Science and Business Media LLC}, author={Harris, J. Milton and Chess, Robert B.}, year={2003}, month=mar, pages={214–221} }